ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23 | -85.9% | 2,073 | -72.9% | 0.00% | -100.0% |
| Q2 2023 | $163 | -51.3% | 7,638 | -7.8% | 0.00% | -66.7% |
| Q1 2023 | $335 | -18.9% | 8,284 | -6.7% | 0.00% | -25.0% |
| Q4 2022 | $413 | -99.9% | 8,881 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $461,000 | +15.0% | 8,881 | +4.7% | 0.00% | 0.0% |
| Q2 2022 | $401,000 | -32.9% | 8,482 | +1.0% | 0.00% | -20.0% |
| Q1 2022 | $598,000 | -54.3% | 8,396 | -52.0% | 0.01% | 0.0% |
| Q4 2021 | $1,308,000 | +155.5% | 17,496 | +94.3% | 0.01% | +25.0% |
| Q3 2021 | $512,000 | +27.0% | 9,004 | -1.6% | 0.00% | +33.3% |
| Q2 2021 | $403,000 | +94.7% | 9,153 | +173.4% | 0.00% | -25.0% |
| Q4 2019 | $207,000 | -23.9% | 3,348 | +3.7% | 0.00% | -33.3% |
| Q2 2019 | $272,000 | +4.2% | 3,228 | +18.0% | 0.01% | 0.0% |
| Q1 2019 | $261,000 | -17.1% | 2,736 | +0.8% | 0.01% | -25.0% |
| Q2 2018 | $315,000 | – | 2,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |